Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2

Acta Neurologica Scandinavica

Volumn 133, Issue 6, 2016, Pages 475-480

  Farschtschi, S ^a   Merker, V L ^b   Wolf, D ^c   Schuhmann, M ^d   Blakeley, J ^c   Plotkin, S R ^b   Hagel, C ^a   Mautner, V F ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Bevacizumab; Ependymoma; Neurofibromatosis; Neurofibromatosis type 2; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; KDR PROTEIN, HUMAN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; BRAIN RADIOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFECT; EPENDYMOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEUROFIBROMATOSIS TYPE 2; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; RECTUM HEMORRHAGE; RETROSPECTIVE STUDY; SYMPTOMATOLOGY; TREATMENT RESPONSE; TUMOR VOLUME; COMPLICATION; GENETICS; METABOLISM; NEUROFIBROMATOSIS 2; PATHOLOGY; SPINAL CORD NEOPLASMS;

ADOLESCENT; ADULT; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; EPENDYMOMA; FEMALE; HUMANS; MALE; NEUROFIBROMATOSIS 2; SPINAL CORD NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84941671344     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12490     Document Type: Note

References (15)

1. Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 2005;26:93-7.
2. Mautner VF, Lindenau M, Baser ME et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 1996;38:880-5.
3. Mautner VF, Tatagiba M, Lindenau M et al. Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety. AJR Am J Roentgenol 1995;165:951-5.
4. Plotkin SR, O'Donnell CC, Curry WT, Bove CM, MacCollin M, Nunes FP. Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients. J Neurosurg Spine 2011;14:543-7.
5. Hagel C, Stemmer-Rachamimov AO, Bornemann A et al. Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated gliomas to be spinal ependymomas. Neuropathology 2012;32:611-6.
6. Lee SH, Chung CK, Kim CH et al. Long-term outcomes of surgical resection with or without adjuvant radiation therapy for treatment of spinal ependymoma: a retrospective multicenter study by the Korea Spinal Oncology Research Group. Neuro Oncol 2013;15:921-9.
7. Epstein FJ, Farmer JP, Freed D. Adult intramedullary spinal cord ependymomas: the result of surgery in 38 patients. J Neurosurg 1993;79:204-9.
8. Plotkin SR, Stemmer-Rachamimov AO, Barker FG et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009;361:358-67.
9. Plotkin SR, Merker VL, Halpin C et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 2012;33:1046-52.
10. Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 2005;19(4 Suppl 3):7-16.
11. Green RM, Cloughesy TF, Stupp R et al. Bevacizumab for recurrent ependymoma. Neurology 2009;73:1677-80.
12. Gururangan S, Fangusaro J, Young PT et al. Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma-a Pediatric Brain Tumor Consortium study. Neuro Oncol 2012;14:1404-12.
13. Mautner VF, Nguyen R, Kutta H et al. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 2010;12:14-8.
14. van den Bent MJ, Wefel JS, Schiff D et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 2011;12:583-93.
15. Chan AS, Leung SY, Wong MP et al. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol 1998;22:816-26.